

Jury Is Still Out on Viability of Health Courts

BY ALICIA AULT

Associate Editor, Practice Trends

WASHINGTON — The concept of using administrative law judges instead of civil jury trials to settle malpractice suits has gained some admirers in the U.S. Congress and generated interest among state legislatures. But it is uncertain whether such a system is the solution to skyrocketing malpractice premiums and jury awards, according to academics, attorneys, and consumer and legislative representatives who met at a meeting sponsored by Common Good and the Harvard School of Public Health, Boston.

Under the “health court” concept, fleshed out earlier this year by Michelle Mello and David Studdert of Harvard, specially trained judges would make compensation decisions according to whether an injury was “avoidable” or “preventable” (Milbank Quarterly 2006;3:459-92). The plaintiff would have to show that the injury would not have happened if best practices were followed. Impartial experts would help set compensation, and decisions would be made quickly.

Such a system would likely increase the number of people eligible for compensation, but decrease the size of awards, Ms. Mello said.

Unlike the current tort system, a health court system could also help deter medical errors by collecting data that would then be given back to hospitals and practitioners for root-cause analyses, she explained.

In 2005, Sen. Michael Enzi (R-Wyo.) and Sen. Max Baucus (D-Mont.) introduced the Fair and Reliable Medical Justice Act (S. 1337), which would provide money for demonstration projects on alternative methods to address malpractice, including health courts. The Senate Health, Education, Labor, and Pensions Committee held a hearing on the bill in June 2006, but there has been no further action.

At the symposium, Stephen Northrup, the health policy staff director for that committee, said it is not clear whether the newly Democratic-controlled Congress will consider alternatives such as health courts. Because Democrats are unlikely to approve of caps on damages as a tort reform, he said, it is incumbent on physicians to promote alternatives.

The National Committee for Quality Assurance supports the move toward an administrative court, said NCQA general counsel Sharon Donohue. But there is no evidence that rewards will decrease, and with an expanding number of claimants, malpractice premiums might still increase because they are based on the number of claims paid, she said.

Some consumer groups oppose the idea. Linda Kenney, president of the advocacy group Medically Induced Trauma Support Services, said that patients should not be required to start the claims process, as is proposed. An audience member representing Consumers Union said that her group did not like the idea of taking away a patient’s right to a jury trial.

Dr. Dennis O’Leary, president of the Joint Commission on Accreditation of Healthcare Organizations, also said he

saw some basic impediments to using the courts to improve patient safety. Overall, 85% of errors are due to systems issues; only 15% are competency related, so solutions should focus on systems design, Dr. O’Leary said.

Despite JCAHO’s voluntary reporting requirements of the last 10 years, there are few reports of adverse events—maybe 450-500 a year, he said. Most reports concern errors that are not easy to hide, such as patient suicides—the top category—and

surgical misadventures, the number two category, Dr. O’Leary said.

Several states have looked at or adopted “I’m sorry” statutes to address malpractice. Under the 2003 law, physicians can apologize, admit fault, and explain the cause of an error without it being held against them in court. The law has reduced the number of cases going to trial in Colorado.

So far, 2,835 of the 6,000 physicians covered by COPIC Insurance Co., a malpractice insurer, have participated in a

program implementing the law, said George Dikeou, a consultant to the company. Participating physicians have had at least 3,200 discussions with patients, and in about 2,000 cases, the discussion was all that was needed to close the case, he said.

The insurer is authorized to pay up to \$30,000 per case; the average payout over 711 cases has been about \$5,300, Mr. Dikeou said. Of 116 cases that went to court, 54 were closed without payment and without attorney involvement. ■


Whether they have mild, moderate, or severe atopic dermatitis...

Your patients have the right

to bare arms...



CUTIVATE LOTION is the



- **First-line therapy**
 - Significant results as early as Week 2... sustained relief through Week 4^{1,2}
- **1 year of age and older³**
 - Proven safe for adults and children—no evidence of HPA*-axis suppression^{3,4}
- **Once-daily**
 - Emollient-rich formulation contains dimethicone

CUTIVATE LOTION is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 1 year of age and older.

Not for ophthalmic, oral, or intravaginal use, or for use by patients with a hypersensitivity to any of its components. In clinical studies, drug-related side effects following the use of CUTIVATE LOTION consisted primarily of localized burning and stinging, and were usually mild and self-limiting. No skin atrophy, changes in pigmentation, or evidence of HPA-axis suppression were observed following the use of CUTIVATE LOTION in these studies. Adrenal suppression has been observed in studies with other fluticasone propionate topical formulations.

*HPA = hypothalamic-pituitary-adrenal.

References: 1. Eichenfield LF, Miller BH, on behalf of a Cutivate Lotion Study Group. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. *J Am Acad Dermatol*. 2006;54:715-717. 2. Data on file, PharmaDerm. 3. Cutivate® [prescribing information]. Duluth, Ga: PharmaDerm, a division of ALTANA Inc; 2006. 4. Hebert AA, Friedlander SF, Allen DB, for the Fluticasone Pediatrics Safety Study Group. Topical fluticasone propionate lotion does not cause HPA axis suppression. *J Pediatr*. 2006;149:378-382.

Please see next page for brief summary of full Prescribing Information.



CUTIVATE LOTION is a registered trademark of PharmaDerm, a division of ALTANA Inc. ©2006 PharmaDerm, Duluth, GA 30096. All rights reserved. 98CL291006

Once-daily
CUTIVATE® LOTION, 0.05%
(fluticasone propionate lotion)

First-Line Emollient-Rich Relief™